• Treatment options for patients with dementia are limited. This article provides an overview of possible interventions, both pharmaceutical and nonpharmaceutical, for Alzheimer's disease, vascular dementia and mixed dementia. • Pharmaceutical treatment options include cholinesterase inhibitors, memantine and experimental medication. Cholinesterase inhibitors are only recommended for Alzheimer's disease and mixed dementia, not for vascular dementia or mild cognitive impairment. There is no proof of effectiveness for the other pharmaceutical options. • Interventions towards cardiovascular risk factors do not slow down cognitive decline. • Evidence is still lacking for other nonpharmaceutical interventions such as memory training and dietary ...
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise...
Vascular cognitive impairment (VCI), encompassing vascular dementia, has been claimed as the “second...
Dementia is an acquired global impairment of cognitive capacities. Approximately 5% of people aged o...
• Treatment options for patients with dementia are limited. This article provides an overview of pos...
Background: Practising physicians frequently seek advice on the most effective interventions for dem...
Item does not contain fulltextBackground: Until now, multiple reviews on the pharmacological treatme...
Objectives: In this paper we aim to: (1) identify and review midlife risk factors that may con-tribu...
The pharmacological treatment of dementias aims to improve cognitive deficits, activities of daily l...
Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the ...
This review aims to evaluate the existing evidence for pharmacotherapy for management of dementia. D...
Family physicians play a crucial role in the management and ongoing care of patients with Alzheimer ...
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise...
The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review the ...
Background: Alzheimer’s disease (AD) that is identified by progressive cognitive deficit and behavio...
The number of people with dementia is escalating globally. About 47 million people were living with ...
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise...
Vascular cognitive impairment (VCI), encompassing vascular dementia, has been claimed as the “second...
Dementia is an acquired global impairment of cognitive capacities. Approximately 5% of people aged o...
• Treatment options for patients with dementia are limited. This article provides an overview of pos...
Background: Practising physicians frequently seek advice on the most effective interventions for dem...
Item does not contain fulltextBackground: Until now, multiple reviews on the pharmacological treatme...
Objectives: In this paper we aim to: (1) identify and review midlife risk factors that may con-tribu...
The pharmacological treatment of dementias aims to improve cognitive deficits, activities of daily l...
Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the ...
This review aims to evaluate the existing evidence for pharmacotherapy for management of dementia. D...
Family physicians play a crucial role in the management and ongoing care of patients with Alzheimer ...
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise...
The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review the ...
Background: Alzheimer’s disease (AD) that is identified by progressive cognitive deficit and behavio...
The number of people with dementia is escalating globally. About 47 million people were living with ...
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise...
Vascular cognitive impairment (VCI), encompassing vascular dementia, has been claimed as the “second...
Dementia is an acquired global impairment of cognitive capacities. Approximately 5% of people aged o...